www.nascentbiotech.com
Open in
urlscan Pro
209.182.193.252
Public Scan
Submitted URL: http://www.nascentbiotech.com/
Effective URL: https://www.nascentbiotech.com/
Submission: On December 28 via api from US — Scanned from DE
Effective URL: https://www.nascentbiotech.com/
Submission: On December 28 via api from US — Scanned from DE
Form analysis 0 forms found in the DOM
Text Content
* Products * Pritumumab * CLNH5 * MultiPharm * Investors * Corporate Governance * Contact Investor Relations * News * About * Corporate Management * Board of Directors * Science Advisory Board * Contact * Products * Pritumumab * CLNH5 * MultiPharm * Investors * Corporate Governance * Contact Investor Relations * News * About * Corporate Management * Board of Directors * Science Advisory Board * Contact PRITUMUMAB IS A PROPRIETARY MONOCLONAL ANTIBODY (MAB) TARGETING A NOVEL ANTIGEN ON CANCER CELLS. PRITUMUMAB HAS RECEIVED FDA ORPHAN DRUG STATUS LATEST NEWS FROM NASCENT BIOTECH NASCENT BIOTECH ANNOUNCES APPOINTMENT OF DR. IVAN BABIC TO SCIENTIFIC ADVISORY BOARD December 20, 2022 Corporate News, Press Releases, Science News VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...] 0 NASCENT BIOTECH RECEIVES NOTICE OF THE ISSUANCE OF US PATENT NO.11,494,394 November 1, 2022 Corporate News, News, Press Releases, Science News NASCENT BEGINS ENROLLMENT OF FINAL PATIENT COHORT TO COMPLETE PHASE ONE CLINICAL RESEARCH October 4, 2022 Corporate News, Press Releases, Science News Load More DELIVERING HUMAN ANTIBODIES FOR THE TREATMENT OF CANCER © NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.